Get it on Google Play

Pharvaris publishes phase 3 deucrictibant HAE study results in The Lancet

October 8, 2026 6:35 PM EDT Send to a Friend
Pharvaris (Nasdaq: PHVS) announced that results from its RAPIDe-3 phase 3 study evaluating oral deucrictibant immediate-release (IR) capsules for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login